focus -WSS

focus

author：hotspot 2025-09-30 20:35:30 - browse：8315

Matts Take Column Illustration — Molly Ferguson for STAT

The news that the weight loss drug Wegovy reduced the risk of heart attacks and strokes in overweight volunteers opens up the door to vastly expanded use of the drug and medicines like it, known as GLP-1 medicines.

That could have a big, positive impact on public health, and it will very likely swell the coffers of the pharmaceutical companies that make these medicines, including Wegovy’s maker, Novo Nordisk, and Eli Lilly, now the most valuable drug company in history thanks largely to hopes for its GLP-1, Mounjaro. These are medicines that could save lives, make money, and perhaps reshape our culture. But they are also, we are learning, not without risk.

So what’s next?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： CRISPR gene editing developments we’re watching in 2024

WSS

SNAP should offer more nutrition education

Arc Institute generative AI designs new CRISPR systems

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Editas, Vertex strike deal on CRISPR

HIV vaccine remains elusive. Immunologists keep trying new ideas

Solving academic medical centers' existential crisis

hotspot

focus

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

It's time to retire 'poor historian' from clinicians' vocabularies

In Memoriam: Notable people who died in 2023

Can sheer will power keep patients alive in their dying hours?

Bright Health sells Medicare Advantage business to Molina

Carvykti CAR

Sports medicine is finally prioritizing gender equality

David Ricks of Eli Lilly: best biopharma CEO of 2023

Novavax promises a turnaround & Lilly roils the obesity market

CRISPR gene editing developments we’re watching in 2024

focus

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Medicare Advantage beneficiaries sue Humana over algorithm use

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Military medical care influenced by rank and race, new study finds

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Medicare drug price negotiation hasn't dried up venture capital

entertainment

hotspot

leisure time

leisure time